3,4,3',4'-tetrachloroazoxybenzene
unwanted contaminant found in commercial synthesis of dichloroaniline or herbicides made from dichloroaniline; implicated in outbreak of acne in chemical workers
Networked: 9
relevant articles (1 outcomes,
1 trials/studies)
Relationship Network
Bio-Agent Context: Research Results
Related Diseases
1. | Body Weight (Weight, Body)
01/01/1982
- " In addition, TCAOB causes a decrease in the body weight gain and a decrease in the weights of major organs in the weanling animals. " 05/01/1984
- " Treatment with TCDD (30 micrograms/kg body weight) and 3,3',4,4'-tetrachloroazoxy-benzene (TCAOB)(8 mg/kg) on day 12 caused cleft palate in 75-100% of all NMRI fetuses, irrespective of whether they had remained in their own (NMRI) dams or as aliens in DBA dams. " 05/01/1999
- " In the rat studies, the major effects included death in the 30 mg TCAOB/kg dose group; at lower exposure levels, a decrease in body weight gain, a decrease in thymus weight, an increase in liver weight, an increase in hematopoietic cell proliferation in the spleen and liver, a responsive anemia, a decrease in platelet counts, a chronic active inflammation of the vasculature in the lung, an increase in cardiomyopathy, hyperplasia of the forestomach, and a marked decrease in circulating thyroxine concentrations were observed. "
|
2. | Cardiomyopathies (Cardiomyopathy)
05/01/1999
- " In the rat studies, the major effects included death in the 30 mg TCAOB/kg dose group; at lower exposure levels, a decrease in body weight gain, a decrease in thymus weight, an increase in liver weight, an increase in hematopoietic cell proliferation in the spleen and liver, a responsive anemia, a decrease in platelet counts, a chronic active inflammation of the vasculature in the lung, an increase in cardiomyopathy, hyperplasia of the forestomach, and a marked decrease in circulating thyroxine concentrations were observed. "
|
3. | Inflammation (Inflammations)
05/01/1999
- " In the rat studies, the major effects included death in the 30 mg TCAOB/kg dose group; at lower exposure levels, a decrease in body weight gain, a decrease in thymus weight, an increase in liver weight, an increase in hematopoietic cell proliferation in the spleen and liver, a responsive anemia, a decrease in platelet counts, a chronic active inflammation of the vasculature in the lung, an increase in cardiomyopathy, hyperplasia of the forestomach, and a marked decrease in circulating thyroxine concentrations were observed. "
|
4. | Hyperplasia
05/01/1999
- " In the rat studies, the major effects included death in the 30 mg TCAOB/kg dose group; at lower exposure levels, a decrease in body weight gain, a decrease in thymus weight, an increase in liver weight, an increase in hematopoietic cell proliferation in the spleen and liver, a responsive anemia, a decrease in platelet counts, a chronic active inflammation of the vasculature in the lung, an increase in cardiomyopathy, hyperplasia of the forestomach, and a marked decrease in circulating thyroxine concentrations were observed. "
|
5. | Anemia
05/01/1999
- " In the rat studies, the major effects included death in the 30 mg TCAOB/kg dose group; at lower exposure levels, a decrease in body weight gain, a decrease in thymus weight, an increase in liver weight, an increase in hematopoietic cell proliferation in the spleen and liver, a responsive anemia, a decrease in platelet counts, a chronic active inflammation of the vasculature in the lung, an increase in cardiomyopathy, hyperplasia of the forestomach, and a marked decrease in circulating thyroxine concentrations were observed. "
|
|
Related Drugs and Biologics
1. | Thyroxine (Levothyroxine)
|
2. | 3,4,3',4'-tetrachloroazobenzene
|
3. | Polychlorinated Dibenzodioxins (TCDD)
|
4. | Herbicides
|
5. | 3,4,3',4'-tetrachloroazoxybenzene
|
6. | Eflornithine (Ornidyl)
|
7. | 3,4-dichloroaniline
|
8. | 2,3,7,8-tetrachlorodibenzofuran
|
|